Translational Control of COVID-19 and Its Therapeutic Implication

Front Immunol. 2022 Mar 29:13:857490. doi: 10.3389/fimmu.2022.857490. eCollection 2022.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, which has broken out worldwide for more than two years. However, due to limited treatment, new cases of infection are still rising. Therefore, there is an urgent need to understand the basic molecular biology of SARS-CoV-2 to control this virus. SARS-CoV-2 replication and spread depend on the recruitment of host ribosomes to translate viral messenger RNA (mRNA). To ensure the translation of their own mRNAs, the SARS-CoV-2 has developed multiple strategies to globally inhibit the translation of host mRNAs and block the cellular innate immune response. This review provides a comprehensive picture of recent advancements in our understanding of the molecular basis and complexity of SARS-CoV-2 protein translation. Specifically, we summarize how this viral infection inhibits host mRNA translation to better utilize translation elements for translation of its own mRNA. Finally, we discuss the potential of translational components as targets for therapeutic interventions.

Keywords: COVID-19; SARS-CoV-2; inhibitor; interferon; translation.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Humans
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • RNA, Viral
  • Ribosomes / metabolism
  • SARS-CoV-2

Substances

  • RNA, Messenger
  • RNA, Viral